首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Evaluation of avoralstat an oral kallikrein inhibitor in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

【2h】

Evaluation of avoralstat an oral kallikrein inhibitor in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

机译：口服激肽释放酶抑制剂avoralstat在3期遗传性血管性水肿预防试验中的评估：OPuS-2研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundEffective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1‐INH‐HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small molecule inhibitor of plasma kallikrein. This study (OPuS‐2) evaluated the efficacy and safety of prophylactic avoralstat 300 or 500 mg compared with placebo.

机译：背景有效抑制血浆激肽释放酶可能通过减少血管性水肿发作的频率而对C1抑制剂（C1-INH-HAE）缺乏的遗传性血管性水肿患者产生重大益处。 Avoralstat是血浆激肽释放酶的小分子抑制剂。这项研究（OPuS-2）评估了与安慰剂相比，预防性avoralstat 300或500 mg的疗效和安全性。

著录项

期刊名称 Wiley-Blackwell Online Open
作者
M. A. Riedl; E. Aygören‐Pürsün; J. Baker; H. Farkas; J. Anderson; J. A. Bernstein; L. Bouillet; P. Busse; M. Manning; M. Magerl; M. Gompels; A. P. Huissoon; H. Longhurst; W. Lumry; B. Ritchie; R. Shapiro; D. Soteres; A. Banerji; M. Cancian; D. T. Johnston; T. J. Craig; D. Launay; H. H. Li; M. Liebhaber; T. Nickel; J. Offenberger; W. Rae; R. Schrijvers; M. Triggiani; H. J. Wedner; S. Dobo; M. Cornpropst; D. Clemons; L. Fang; P. Collis; W. P. Sheridan; M. Maurer;
展开▼
作者单位

展开▼
年(卷),期 -1(73),9
年度 -1
页码 1871–1880
总页数 10
原文格式 PDF
正文语种
中图分类
关键词
C1 inhibitor hereditary angioedema oral kallikrein inhibitor prophylaxis;

机译：C1抑制剂;遗传性血管性水肿;口服激肽释放酶抑制剂;预防;

相似文献

外文文献
中文文献
专利

1. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS OPuS ‐2?study [J] . Riedl M. A., Ayg?ren‐Pürsün E., Baker J., Allergy . 2018,第9期

机译：口服Kallikrein抑制剂的Avoralstat评估，在第3期遗传性血管型预防试验中：Opus Opus -2？研究
2. Prophylaxis of hereditary angioe-dema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat [J] . Aygoeren-Puersuen Emel, Magerl Markus, Graff Jochen, The Journal of Allergy and Clinical Immunology . 2016,第3期

机译：预防遗传性血管性水肿发作：avoralstat抑制口服血浆激肽释放酶的随机试验
3. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema [J] . Aygoeren-Puersuen E., Bygum A., Grivcheva-Panovska V., The New England journal of medicine . 2018,第4期

机译：口腔血浆Kallikrein抑制剂在遗传血管后血统的预防
4. PHASE I/II TRIAL OF DUAL AGENT POLYAMINE DEPLETION THERAPY FOR FELINE ORAL SQUAMOUS CELL CARCINOMA [C] . Katherine A Skorupski, Thomas OBrien, Mark Burns, Annual conference of the Veterinary Cancer Society . 2008

机译：双药剂多胺耗竭治疗猫鳞状鳞状细胞癌的I / II试验
5. Screening of natural products for their effect on kallikrein-kinin system: Potential implications in the treatment of hereditary angioedema. [D] . Madkhali, Hassan Abdu. 2015

机译：筛选天然产物对激肽释放酶激肽系统的影响：遗传性血管性水肿治疗的潜在影响。
6. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial [O] . Donald S. Levy, Henriette Farkas, Marc A. Riedl, 2020

机译：皮下C1抑制剂对遗传性血管性水肿妇女的长期疗效和安全性：一项3期试验的开放标签扩展研究的亚组分析
7. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study [O] . M. A. Riedl, E. Aygören-Pürsün, J. Baker, 2018

机译：口服Kallikrein抑制剂的Avoralstat评估，在第3期遗传性血统血症预防试验中：Opus-2研究

Evaluation of avoralstat an oral kallikrein inhibitor in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

摘要

著录项

相似文献

相关主题

期刊订阅